These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38757351)

  • 1. Parkinson's Disease Associated with G2019S LRRK2 Mutations without Lewy Body Pathology.
    Jackson LM; Woodruff BK; Tremblay C; Shill HA; Beach TG; Serrano GE; Adler CH
    Mov Disord Clin Pract; 2024 Jul; 11(7):874-878. PubMed ID: 38757351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.
    Gaig C; Martí MJ; Ezquerra M; Rey MJ; Cardozo A; Tolosa E
    J Neurol Neurosurg Psychiatry; 2007 Jun; 78(6):626-8. PubMed ID: 17210620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT.
    Ling H; Kara E; Bandopadhyay R; Hardy J; Holton J; Xiromerisiou G; Lees A; Houlden H; Revesz T
    Neurobiol Aging; 2013 Dec; 34(12):2889.e5-9. PubMed ID: 23664753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.
    Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V
    Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology.
    Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R
    Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease.
    Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
    Gaig C; Ezquerra M; Martí MJ; Valldeoriola F; Muñoz E; Lladó A; Rey MJ; Cardozo A; Molinuevo JL; Tolosa E
    J Neurol Sci; 2008 Jul; 270(1-2):94-8. PubMed ID: 18353371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2.
    Devine MJ; Lewis PA
    FEBS J; 2008 Dec; 275(23):5748-57. PubMed ID: 19021752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.
    Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R
    Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies.
    Perry G; Zhu X; Babar AK; Siedlak SL; Yang Q; Ito G; Iwatsubo T; Smith MA; Chen SG
    Neurodegener Dis; 2008; 5(3-4):222-4. PubMed ID: 18322396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GTP-binding inhibitors increase LRRK2-linked ubiquitination and Lewy body-like inclusions.
    Thomas JM; Wang X; Guo G; Li T; Dai B; Nucifora LG; Nucifora FC; Liu Z; Xue F; Liu C; Ross CA; Smith WW
    J Cell Physiol; 2020 Oct; 235(10):7309-7320. PubMed ID: 32180220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease.
    Ito G; Utsunomiya-Tate N
    Biomolecules; 2023 May; 13(5):. PubMed ID: 37238714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2.
    Martí-Massó JF; Ruiz-Martínez J; Bolaño MJ; Ruiz I; Gorostidi A; Moreno F; Ferrer I; López de Munain A
    Mov Disord; 2009 Oct; 24(13):1998-2001. PubMed ID: 19735093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?
    Taylor JP; Mata IF; Farrer MJ
    Trends Mol Med; 2006 Feb; 12(2):76-82. PubMed ID: 16406842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.
    Dzamko N; Gysbers AM; Bandopadhyay R; Bolliger MF; Uchino A; Zhao Y; Takao M; Wauters S; van de Berg WD; Takahashi-Fujigasaki J; Nichols RJ; Holton JL; Murayama S; Halliday GM
    Mov Disord; 2017 Mar; 32(3):423-432. PubMed ID: 27911006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data.
    Khan NL; Jain S; Lynch JM; Pavese N; Abou-Sleiman P; Holton JL; Healy DG; Gilks WP; Sweeney MG; Ganguly M; Gibbons V; Gandhi S; Vaughan J; Eunson LH; Katzenschlager R; Gayton J; Lennox G; Revesz T; Nicholl D; Bhatia KP; Quinn N; Brooks D; Lees AJ; Davis MB; Piccini P; Singleton AB; Wood NW
    Brain; 2005 Dec; 128(Pt 12):2786-96. PubMed ID: 16272164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.
    Kalia LV; Lang AE; Hazrati LN; Fujioka S; Wszolek ZK; Dickson DW; Ross OA; Van Deerlin VM; Trojanowski JQ; Hurtig HI; Alcalay RN; Marder KS; Clark LN; Gaig C; Tolosa E; Ruiz-Martínez J; Marti-Masso JF; Ferrer I; López de Munain A; Goldman SM; Schüle B; Langston JW; Aasly JO; Giordana MT; Bonifati V; Puschmann A; Canesi M; Pezzoli G; Maues De Paula A; Hasegawa K; Duyckaerts C; Brice A; Stoessl AJ; Marras C
    JAMA Neurol; 2015 Jan; 72(1):100-5. PubMed ID: 25401511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression.
    Lubben N; Brynildsen JK; Webb CM; Li HL; Leyns CEG; Changolkar L; Zhang B; Meymand ES; O'Reilly M; Madaj Z; DeWeerd D; Fell MJ; Lee VMY; Bassett DS; Henderson MX
    Transl Neurodegener; 2024 Mar; 13(1):13. PubMed ID: 38438877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain.
    Nguyen APT; Daniel G; Valdés P; Islam MS; Schneider BL; Moore DJ
    Hum Mol Genet; 2018 Jan; 27(1):120-134. PubMed ID: 29088368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons.
    Henderson MX; Changolkar L; Trojanowski JQ; Lee VMY
    J Parkinsons Dis; 2021; 11(3):1187-1196. PubMed ID: 33720852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.